16 completed, 5 terminated, 2 recruiting, 1 active not recruiting. 25 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 25 | Completed 16, Terminated 5, Recruiting 2, Active not recruiting 1, Unknown 1 |
| Phase 2 | 9 | Completed 6, Terminated 2, Unknown 1 |
Follow Histiocytoma: new trials by email Literature Review of Histiocytoma trials Research Report on Histiocytoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors OKN4395, Pembrolizumab, Fasting - Solid Tumours, Sarcoma | Phase 1 | Recruiting | Epkin | 146 | 2025-01-23 | 2026-06-11 |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-02-06 | 2026-11-02 |
| Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications BBI-355, Erlotinib, Futibatinib - Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma | Phase 1 | Terminated | Boundless Bio, Inc. | 85 | 2023-03-24 | 2026-08-19 |
| Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma Definitive Surgical Resection, Nanoplexed Poly I:C BO-112, Nivolumab - Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 14 | 2020-10-14 | 2026-03-10 |
| Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas DCC-3014, Avelumab - Sarcoma, Advanced Sarcoma | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 32 | 2020-01-22 | 2025-08-28 |
| A Study of LY3435151 in Participants With Solid Tumors LY3435151, Pembrolizumab - Solid Tumor, Triple-negative Breast Cancer | Phase 1 | Terminated | Eli Lilly and Company | 2 | 2019-10-28 | 2021-08-31 |
| Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas Itacitinib, Laboratory Biomarker Analysis - Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 27 | 2019-09-30 | 2024-05-08 |
| A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) XmAb®23104, Yervoy® (ipilimumab) - Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma | Phase 1 | Completed | Xencor, Inc. | 198 | 2019-05-01 | 2024-07-05 |
| CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma CAB-AXL-ADC, PD-1 inhibitor - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | Phase 1 / Phase 2 | Completed | BioAtla, Inc. | 245 | 2018-02-15 | 2025-09-23 |
| Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Nivolumab 100 MG/10 ML [Opdivo], Epirubicin - Soft Tissue Sarcoma, Bone Sarcoma | Phase 1 / Phase 2 | Completed | Grupo Espanol de Investigacion en Sarcomas | 197 | 2017-05-31 | 2024-08-13 |
| Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma | Phase 1 | Completed | OHSU Knight Cancer Institute | 16 | 2017-03-10 | 2023-08-16 |
| Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Pazopanib, Pazopanib Hydrochloride, Sapanisertib - High Grade Sarcoma, Metastatic Leiomyosarcoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 151 | 2015-11-30 | 2022-08-23 |
| ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors ABBV-085 - Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma | Phase 1 | Completed | AbbVie | 85 | 2015-09-18 | 2019-04-05 |
| Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors nab-paclitaxel - Neuroblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Completed | Celgene | 107 | 2013-12-04 | 2019-12-27 |
| Autologous Dendritic Cell Vaccine in Patients With Soft Tissue Sarcoma Autologous dendritic cell vaccine - Sarcoma, Neoplasms, Connective and Soft Tissue | Phase 1 / Phase 2 | Unknown | N.N. Petrov National Medical Research Center of Oncology | 48 | 2013-06-01 | 2019-11-20 |
| Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination - Sarcoma, Leiomyosarcoma | Phase 1 / Phase 2 | Terminated | Memorial Sloan Kettering Cancer Center | 5 | 2011-08-01 | 2018-01-11 |
| Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study - Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 78 | 2010-06-01 | 2018-08-15 |
| Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma temsirolimus plus liposomal doxorubicin - Sarcoma | Phase 1 / Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 24 | 2009-09-01 | 2019-03-11 |
| Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Cixutumumab, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis - Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2008-06-01 | 2016-05-17 |
| Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors belinostat, 5-Fluorouracil (5-FU) - Tumor | Phase 1 | Completed | Valerio Therapeutics | 35 | 2005-09-01 | 2015-07-08 |
Showing 20 of 25. Sign in to see all of them.
Histiocytoma, Malignant Fibrous (24) · Sarcoma (19) · Leiomyosarcoma (18) · Sarcoma, Synovial (13) · Liposarcoma (12) · Neurofibrosarcoma (11) · Dermatofibrosarcoma (10) · Fibrosarcoma (9) · Hemangiosarcoma (8) · Chondrosarcoma (7) · Osteosarcoma (7) · Rhabdomyosarcoma (7) · Neoplasms (6) · Sarcoma, Alveolar Soft Part (5) · Squamous Cell Carcinoma of Head and Neck (5)
Neoplasms by Histologic Type (25) · Neoplasms, Connective Tissue (25) · Neoplasms, Fibrous Tissue (25) · Neoplasms, Connective and Soft Tissue (24) · Neoplasms (19) · Neoplasms, Muscle Tissue (19) · Neoplasms, Nerve Tissue (15) · Neoplasms, Adipose Tissue (13) · Nervous System Diseases (12) · Nervous System Neoplasms (12) · Peripheral Nervous System Neoplasms (12) · Neoplasms by Site (11) · Nerve Sheath Neoplasms (11) · Neurofibroma (11)
Doxorubicin (4) · Ifosfamide (2) · Nivolumab (2) · Radiotherapy (2) · liposomal doxorubicin (2) · pazopanib (2) · pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · Albumin-Bound Paclitaxel (1) · Angptl4 protein, mouse (1) · BO-112 (1) · Biopsy (1) · Celecoxib (1) · Chemotherapy, Adjuvant (1)
National Cancer Institute (NCI) (6) · European Organisation for Research and Treatment of Cancer - EORTC (2) · Memorial Sloan Kettering Cancer Center (2) · AbbVie (1) · BioAtla, Inc. (1) · Boundless Bio, Inc. (1) · Celgene (1) · Eli Lilly and Company (1) · Epkin (1) · Fred Hutchinson Cancer Center (1) · Grupo Espanol de Investigacion en Sarcomas (1) · Jonsson Comprehensive Cancer Center (1) · N.N. Petrov National Medical Research Center of Oncology (1) · OHSU Knight Cancer Institute (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (21) · United Kingdom (4) · France (3) · Spain (3) · Denmark (2) · Italy (2) · Australia (1) · Belgium (1) · Canada (1) · Germany (1) · Hong Kong (1) · Japan (1) · Netherlands (1) · Russia (1) · Switzerland (1)
Aaron H. Wolfson, MD (1) · Alba Rubio (1) · Antonio Casado (1) · Candace L Haddox (1) · Chet Bohac, MD, MSc (1) · Claudia Valverde (1) · Cristina Mata (1) · David M Loeb, MD, PhD (1) · Elizabeth Lowe (1) · Emanuela Palmerini (1)
PMID 31401903, PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15592836, PMID 19088049, PMID 23382028, PMID 25858498, PMID 30410720, PMID 32554315, PMID 33203665, PMID 35260879, PMID 38579194, PMID 39356980, PMID 41836677
2015 (1), K08CA245181 (1), N01CM00071 (1), N01CM62206 (1), P30CA008748 (1), P30CA014599 (1), U01CA069856 (1), U10CA180821 (1), UM1CA186709 (1)